Asia to be the Fastest Growing Region in Global Diabetic Nephropathy Market

With 366 million people expected to be affected by diabetes in 2030, the diabetic nephropathy market is expected to grow consistently. The market was worth US$2,262.2 million in 2014 and, at a 5.6% CAGR during the period between 2014 and 2020, it is expected to reach US$3,145.9 million by 2020.

Request for Sample Report:http://www.mrrse.com/sample/119

Diabetic nephropathy is a serious condition associated with the kidneys, where increased levels of protein, especially albumin, are present in urine. In a patient affected with diabetic nephropathy, albumin in the urine increases to potentially fatal amounts. The increasing prevalence of diabetes has primarily fueled the diabetic nephropathy market. According to the World Health Organization (WHO), about 9% adults aged above 18 years were affected by diabetes worldwide in 2014. By 2030, the disease is expected to be the seventh leading cause of death worldwide. As diabetes is commonly associated with obesity, the diabetic nephropathy market is estimated to grow along with the rising number of obese people across the globe. The increasing investment in research and development of drugs to treat diabetic nephropathy will boost the overall market. Nowadays, there is increased awareness among people about diabetes and kidney-related disorders. This will further help the market grow, particularly in previously unexplored regions.

However, the long duration of clinical trials, in conjunction with the strict regulatory requirements by authorities such as the European Medicines Agency and the U.S. Food and Drug Administration will slow down the growth of the diabetic nephropathy market. Lack of comprehensive therapeutic management will also affect the growth of the overall market. The increasing usage of combination therapy to treat the condition is gaining popularity and is expected to be the key market trend during the forecast horizon.

Angiotensin-converting Enzyme (ACE) Inhibitors to be Key Disease Modifying Therapy

The diabetic nephropathy market has been segmented on the basis of the disease modifying therapy into angiotensin receptor blockers, angiotensin-converting enzyme (ACE) inhibitors, calcium channel blockers, renin inhibitors, diuretics, antioxidant inflammation modulator, monocyte chemoattractant proteins inhibitor, connective tissue growth factor inhibitors, G-protein coupled receptors, and endothelin-A receptor antagonist. As hypertension is usually a consequence of diabetic nephropathy, use of antihypertensive agents is usually prescribed in the treatment. ACE inhibitors can reduce the level of progression of the disease by a greater degree than other hypertensive agents and hence this segment is expected to grow significantly.

North America Leads Global Diabetic Nephropathy Market

Globally, the diabetic nephropathy market has been divided into Asia, North America, and Europe. North America has been leading the overall market, followed by Europe. According to the American Diabetes Association, in the U.S. alone, around 40% of new cases of diabetic nephropathy have been reported in the recent past. The U.S. and Canada will contribute significantly to the diabetic nephropathy market in North America. Asia is expected to be the fastest growing region of the market during the forecast period, with rising number of patients in Japan, China, and India affected with the condition.

Key Players of the Diabetic Nephropathy Market

Some of the key players of the diabetic nephropathy market include Pfizer Inc., Novartis AG, Sanofi, and Bayer AG, among others.

Browse the full Global Diabetic Nephropathy Market report at http://www.mrrse.com/diabetic-nephropathy-market

Market Research Reports Search Engine (MRRSE) is an industry-leading database of market intelligence reports. MRRSE is driven by a stellar team of research experts and advisors trained to offer objective advice. Our sophisticated search algorithm returns results based on the report title, geographical region, publisher, or other keywords.

MRRSE partners exclusively with leading global publishers to provide clients single-point access to top-of-the-line market research. MRRSE’s repository is updated every day to keep its clients ahead of the next new trend in market research, be it competitive intelligence, product or service trends or strategic consulting.

State Tower
90, State Street
Suite 700
Albany, NY – 12207
United States Telephone: +1-518-730-0559
Email: sales@mrrse.com
Follow Us on LinkedIn-https://www.linkedin.com/company/mrrse
Follow Us On Twitter-https://twitter.com/MRRSEmrrse

This release was published on openPR.